Table 1.
US | 2646 |
Follow-up indicated (+) | 249 |
No follow-up indicated (−) | 2397 |
Prevalence | 9.4% |
CT | 2557 |
Follow-up indicated (+) | 324 |
No follow-up indicated (−) | 2233 |
Prevalence | 12.7% |
MR | 797 |
Follow-up indicated (+) | 162 |
No follow-up indicated (−) | 635 |
Prevalence | 20.3% |
All modalities | 6000 |
Follow-up indicated (+) | 735 |
No follow-up indicated (−) | 5265 |
Prevalence | 12.3% |